Fusion to Acquire Ipsen’s IPN-1087 to Expand its Pipeline of Radiopharmaceuticals

Shots:

• Ipsen to receive 400,000 shares at closing and an additional 200,000 shares as milestones, $81.63M as development and regulatory milestones & $423.24M as commercial milestones along with royalties on net sales
• Fusion will be responsible for paying to a third-party licensor up to $84.7M in development milestones and royalties on net sales of products
• IPN-1087 is a small molecule targeting NTSR1. Fusion plans to use IPN-1087 to create an alpha-emitting radiopharmaceutical, FPI-2059, targeting solid tumors expressing NTSR1

Click here ­to­ read full press release/ article | Ref: PRNewswire  | Image: Fusion Pharma